ClinicalTrials.gg

Program

denatonium acetate monohydrate

Its studies are mostly in Hyperphagia · Obesity · Prader-Willi Syndrome, led by Aardvark Therapeutics.

Furthest: phase 3, since Feb 13, 20255 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aardvark Therapeutics50 open or runningphase 3since Feb 13, 2025Oct 19, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2021First study: phase 2 study in ObesityFirst studyNCT05121441 · 20 enrolled · United States
  2. Nov 30, 2021Phase 2 study in Prader-Willi SyndromeNCT05153434 · 19 enrolled · United States
  3. Jan 3, 2022Phase 2 study in ObesityNCT05215847 · 12 enrolled · United States
  4. Feb 13, 2025Phase 3 study in HyperphagiaNCT06828861 · 68 enrolled · United States, Australia, Canada and more
  5. Sep 21, 2025Phase 3 study in HyperphagiaNCT07197034 · 19 enrolled · United States, Australia, Canada and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07197034Hyperphagia · United States, Australia, Canada and more3TerminatedApr 15, 202619
NCT06828861Hyperphagia · United States, Australia, Canada and more3TerminatedMay 7, 202668
NCT05215847Obesity · United States2CompletedFeb 3, 202312
NCT05153434Prader-Willi Syndrome · United States2CompletedSep 24, 202419
NCT05121441Obesity · United States2CompletedNov 9, 202220

How it is read

Names in the registry

  • “ARD-101”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.